Overview

NCI Definition [1]:
Definition: The orally bioavailable copper salt of D-gluconic acid. In addition to its roles as an enzyme cofactor for cytochrome C oxidase and superoxide dismutase, copper forms complexes with the thiocarbamate disulfiram (DSF) forming DSF-copper complexes, which enhances the DSF-mediated inhibition of the 26S proteasome; proteasome inhibition may result in inhibition of cellular protein degradation, cessation of cell cycle progression, inhibition of cellular proliferation, and the induction of apoptosis in susceptible tumor cell populations.

Copper gluconate has been investigated in 3 clinical trials, of which 1 is open and 2 are closed. Of the trials investigating copper gluconate, 1 is phase 1 (1 open) and 2 are phase 2 (0 open).

Glioblastoma, multiple myeloma, and pancreatic adenocarcinoma are the most common diseases being investigated in copper gluconate clinical trials [2].

Drug Details

Synonyms [2]:
cupric gluconate, copper gluconate, copper gluconate
NCIT ID [1]:
C80050

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.